Institutional Core Labs
- iLabs
- Bioanalytics & Single-Cell
- Biospecimen and Translational Genomics
- Flow Cytometry
- Mass Spectometry
- Optical Imaging
- Structural Biology (NMR)
- Structural Biology (X-Ray Crystallography)
Find a Researcher
Research by School
Software Training & Cyberinfrastructure
Additional Resources
Longevity & Aging
Scientists and clinicians in the Barshop Institute for Longevity & Aging Studies and the Glenn Biggs Institute for Alzheimer's and Neurodegernerative diseases are strengthening team science at UT Health San Antonio.
Barshop Institute has the national distinction of two NIA-funded centers, a testing site of the NIA-sponsored Interventions Testing Program, and U.S. Department of Veterans Affairs Geriatric Research, Education, and Clinical Center.
Sudha Seshadri, MD, founding director of the Biggs Institute and principal investigator of the National Institute of Aging Alzheimer's Disease Sequencing Project.
Clinical trial participation is an invaluable way to contribute to the pursuit of new treatments for longevity & aging related diseases. Take action today...volunteer and play a role in finding a cure.
Find
UT Health San Antonio partners with the San Antonio GRECC at the Audie L. Murphy Memorial VA Hospital to initiate clinical research trials to further advanced knowledge of age-related diseases and provide preventive solutions.
Additional Highlights
-
Barshop Institute gains grant award renewals totaling $11 million to support translating research discoveries into healthier aging
The Pepper and Shock grants, which total $11 million over the next five years, support basic research of the biology of aging and translation of discoveries into human application. The renewals further cement the Barshop Institute as one of America’s premier centers of aging research.
Read the story at UT Health San Antonio's Newsroom -
Oral pill slows rate of decline in ALS patients
Although it’s not a cure for ALS, an oral drug slowed patients’ rate of functional decline in a clinical trial that included five patients at UT Health San Antonio. If the finding is repeated in larger trials, the drug could give families more time with their loved ones who have ALS.
Read the article at UT Health San Antonio's Newsroom -
Journal article reviews century of data showing COVID-19 likely to impact the brain
An article published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association cites decades of published scientific evidence to make a compelling case for SARS-CoV-2’s expected long-term effects on the brain and nervous system.
Read the full article at UT Health San Antonio's Newsroom -
$2M grant awarded to study drug’s impact on Alzheimer’s patients
In the war on cancer and other diseases including COVID-19, old drugs approved for other conditions are being studied for new purposes. It’s a strategy that will now be tested in Alzheimer’s disease with a drug called rapamycin.
Read the article at UT Health San Antonio's Newsroom